<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877366</url>
  </required_header>
  <id_info>
    <org_study_id>2019CLI</org_study_id>
    <nct_id>NCT04877366</nct_id>
  </id_info>
  <brief_title>Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia</brief_title>
  <acronym>Stardust</acronym>
  <official_title>A Randomized, Double-blind, Placebo- and Active-Controlled, Single-Center, Three-time-period, Crossover Study to Evaluate the Effects of Sprinkled Format REDUCOSE on Post-Prandial Glycemic Response in Asian Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mechanistic, single-center, double-blind, placebo- and active-controlled,&#xD;
      three-time-period, crossover study to evaluate the effect of sprinkled format REDUCOSE&#xD;
      compared to placebo (double-blind; confirmative) and active control (open-label; acarbose -&#xD;
      explorative) on post prandial glycemia in Asian patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-prandial glycemic excursion (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Incremental area under the curve post-prandial glycemic excursion (iAUC 0-1h, iAUC 0-2h, iAUC 0-3h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2h post-prandial glucose levels (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, and 120 minutes.</time_frame>
    <description>Incremental area under the curve 2h post-prandial glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total glucose (All ARMS)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Total glucose AUC 0-1h (tAUC 0-1h, tAUC 0-2h, tAUC 0-3h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose iCmax (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma glucose iCmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose Tmax (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma glucose Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose AUC (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>protocol states (iAUC 0-3h, tAUC 0-3h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin (All ARMs)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Serum insulin (iAUC 0-3h, iCmax, Tmax, tAUC 0-3h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP-1 (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma GLP-1 (iAUC 0-2h, iCmax, Tmax, tAUC 0-2h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GIP (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma GIP (iAUC 0-2h, iCmax, Tmax, tAUC 0-2h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukin-6 (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma interleukin-6 (IL-6) (iAUC 0-2h, iCmax, Tmax, tAUC 0-2h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Gastric emptying (iAUC 0-1h, tAUC 0-1h, iAUC 0-3h, tAUC 0-3h, Cmax and Tmax for paracetamol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index (ARMs A and B)</measure>
    <time_frame>0, 30, 60, and 120 minutes.</time_frame>
    <description>Matsuda Index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma glucose timepoints (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma glucose at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum insulin timepoints (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Serum insulin at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma GIP and GLP-1 (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma GIP and GLP-1 at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma IL-6 (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma IL-6 at individual timepoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma GLP-1 iAUC (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma GLP-1 (iAUC 0-1h, tAUC 0-1h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma GIP iAUC (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma GIP (iAUC 0-1h, tAUC 0-1h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma IL-6 iAUC (ARMs A and B)</measure>
    <time_frame>0 ,15, 30, 60, 120, and 180 minutes.</time_frame>
    <description>Plasma IL-6 (iAUC 0-4h, tAUC 0-4h, iAUC 0-2h, tAUC 0-2h, iAUC 0-1h, tAUC 0-1h)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Dietary Supplement</condition>
  <arm_group>
    <arm_group_label>ARM A: Sprinkled Format REDUCOSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B: Placebo B: Standard Meal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo matching to the test product will be used as control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C: Placebo C: Acarbose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acarbose 100 mg tablet (provided in open-label format)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement: Sprinkled Format REDUCOSE.</intervention_name>
    <description>2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate</description>
    <arm_group_label>ARM A: Sprinkled Format REDUCOSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference control</intervention_name>
    <description>A placebo matching to the test product will be used as control</description>
    <arm_group_label>ARM B: Placebo B: Standard Meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active comparator</intervention_name>
    <description>Acarbose 100 mg tablet (provided in open-label format)</description>
    <arm_group_label>ARM C: Placebo C: Acarbose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to sign written informed consent prior to study entry.&#xD;
&#xD;
          -  Participants who self-identify as Asian; male or female, &gt;18 years of age.&#xD;
&#xD;
          -  Established diagnosis of type 2 diabetes (documented by either HbA1c 6.5 - 10.0% or a&#xD;
             documented diagnosis of type 2 diabetes).&#xD;
&#xD;
          -  Treatment naïve or on active therapy with metformin at a daily dose of 500-3000 mg at&#xD;
             screening. Dose of metformin must have been stable for at least 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Participants must have a hematocrit value greater than or equal to 34.0% for females&#xD;
             and 40% for males.&#xD;
&#xD;
          -  Participants must have a hemoglobin value greater than or equal to 11.0 g/dL for&#xD;
             females and 13.5 g/dL for males.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting plasma glucose &gt;220 mg/dl at screening.&#xD;
&#xD;
          -  Impaired kidney function, eGFR of &lt;60 mL/min/1.73 m2 at screening.&#xD;
&#xD;
          -  BMI &gt;35 kg/m2.&#xD;
&#xD;
          -  Weight ≤ 50 kg.&#xD;
&#xD;
          -  Elevated liver transaminase &gt; 3 ULN at screening.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) treatment with any oral or injectable&#xD;
             glucose-lowering drug other than metformin.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) injectable insulin therapy.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) weight loss interventions (e.g. dietary weight loss&#xD;
             programs) or any history of bariatric surgery or any documented weight loss &gt;5% within&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Ongoing or recent (i.e. &lt; 3 month) treatment with anorectic drugs, systemic steroids,&#xD;
             medications known to affect gastric motility, or any condition known to affect&#xD;
             gastro-intestinal integrity and food absorption.&#xD;
&#xD;
          -  Major medical/surgical event requiring hospitalization in the last 3 months.&#xD;
&#xD;
          -  Known allergy and intolerance to product components or paracetamol.&#xD;
&#xD;
          -  Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols,&#xD;
             1 dl of red or white wine, or 3 dl of beer.&#xD;
&#xD;
          -  Are unable to comply with protocol procedures in the opinion of the investigator.&#xD;
&#xD;
          -  Have a hierarchical link with the research team members.&#xD;
&#xD;
          -  Positive pregnancy test or breast-feeding at screening.&#xD;
&#xD;
          -  Participants who have been dosed in another clinical study with any investigational&#xD;
             drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to&#xD;
             screening.&#xD;
&#xD;
          -  Donation of blood or significant amount of blood loss within 8 weeks prior to&#xD;
             screening. Participants must also agree to not donate blood within 8 weeks after their&#xD;
             last visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linda Mooney</last_name>
    <phone>908-333-9185</phone>
    <email>Linda.Mooney@us.nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel M Neutel, MD</last_name>
      <phone>714-550-9990</phone>
      <email>NeutelMD@OCResearchCenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temasek Polytechnic</name>
      <address>
        <city>Singapore</city>
        <zip>529757</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalpana Bhaskaran</last_name>
      <email>Kalpana_BHASKARAN@TP.EDU.SG</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

